NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

CompletedN/A

Sponsor: Bristol-Myers Squibb

Conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)

Countries: United States

The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis (PsA)
* Receiving treatment with abatacept
* Receiving treatment with non-targeted DMARD
* Receiving treatment with targeted DMARD

Exclusion Criteria:

-Not applicable

Locations (1)

Lawrenceville, New Jersey, United States